EGFR-TKI plus anlotinib for NSCLC after small cell change
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (a third-generation EGFR-TKI and anlotinib) as maintenance therapy for people with non-small cell lung cancer that has changed into small cell cancer after resistance to EGFR-TKI therapy. It may help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that has changed to small cell cancer after EGFR-TKI resistance.
- Your doctor expects you to live at least 12 more weeks.
- You are in good enough health to be up and about (ECOG 0-2).
- Your bone marrow and organs are working well (based on blood tests).
- You do not have other active cancers, serious infections, or uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (limertinib) plus chemotherapy (carboplatin and etoposide) for people whose EGFR-mutant lung cancer has changed into small cell lung cancer (SCLC) after prior targeted therapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests if adding gumarontinib to a third-generation EGFR-targeted drug can help people with advanced non-small cell lung cancer whose cancer grew while on an EGFR-TKI and has a certain change (MET amplification). The goal is to see if this combination can overcome resistance.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.